The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy targeting prostate-specific membrane antigen (PSMA), in patients with metastatic castration-resistant prostate cancer (mCRPC).
 
Ben Tran
Honoraria - Amgen; Astellas Pharma; Janssen-Cilag; Sanofi; Tolmar
Consulting or Advisory Role - Amgen; Astellas Pharma; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Ipsen; Ipsen; Janssen-Cilag; MSD Oncology; Sanofi; Tolmar
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb; Genentech (Inst); Janssen-Cilag (Inst); Janssen-Cilag (Inst); Merck Sharp & Dohme; Merck Sharp & Dohme; Pfizer (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma
 
Lisa Horvath
Employment - Connected Medical Solutions (I)
Leadership - Connected Medical Solutions (I)
Stock and Other Ownership Interests - Connected Medical Solutions (I)
Consulting or Advisory Role - Imagion Biosystems
Research Funding - Astellas Pharma
Travel, Accommodations, Expenses - Astellas Pharma; Janssen-Cilag; Pfizer
 
Tanya B. Dorff
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Janssen Oncology; Noxopharm; Roche; Seagen
Speakers' Bureau - Exelixis; Prometheus
Research Funding - Bayer; Bristol-Myers Squibb
 
Richard Greil
Honoraria - Abbvie; Amgen; AstraZeneca; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Gilead Sciences; Merck; MSD; Novartis; Roche; Sandoz; Takeda
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Gilead Sciences; Janssen; Merck; MSD; Novartis; Roche; Takeda
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Gilead Sciences (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Roche (Inst); Sandoz (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bristol-Myers Squibb; Celgene; Gilead Sciences; Janssen-Cilag; MSD; Novartis; Roche
 
Jean-Pascal H. Machiels
Consulting or Advisory Role - ALX Oncology; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; CUE Biopharma; Debiopharm Group; Incyte; Innate Pharma; Janssen; Merck Serono; Merck Sharp & Dohme; Nanobiotix; Novartis; Pfizer; Roche
Research Funding - Bayer; Janssen; Novartis; Sanofi
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; MSD; Pfizer
 
Felicia Roncolato
No Relationships to Disclose
 
Karen A. Autio
Research Funding - Amgen (Inst); ARMO BioSciences (Inst); CytomX Therapeutics (Inst); GlaxoSmithKline (Inst); Merck (Inst); Pfizer (Inst); Tizona Therapeutics, Inc. (Inst)
 
Matthew Rettig
Consulting or Advisory Role - Johnson & Johnson
Speakers' Bureau - Bayer; Johnson & Johnson
Research Funding - Johnson & Johnson (Inst); Medivation/Astellas (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - I am a co-inventor on a patent for novel inhibitors of the N-terminal domain of the AR. There are NO commercial partnerships as of yet.
Travel, Accommodations, Expenses - Johnson & Johnson
 
Karim Fizazi
Honoraria - Astellas Pharma; Janssen; Sanofi
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Curevac; ESSA; Janssen Oncology; Orion; Roche/Genentech; Sanofi
Travel, Accommodations, Expenses - Amgen; Janssen
 
Martijn P. Lolkema
Consulting or Advisory Role - Amgen; Astellas Pharma; Bayer; Johnson & Johnson; Pfizer; Roche; Sanofi
Research Funding - Astellas Pharma (Inst); Johnson & Johnson (Inst); Merck Sharp & Dohme (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Ipsen; Merck Sharp & Dohme
 
Anthony C. Fermin
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Mark Salvati
Employment - Amgen
Stock and Other Ownership Interests - Amgen; Johnson & Johnson
 
Hosein Kouros-Mehr
Employment - Amgen
Stock and Other Ownership Interests - Amgen